The FDA will allow health-care providers to administer the shots through intradermal injection, or between the layers of the skin, for adults. This will increase the supply of monkeypox shots by as much as fivefold, the FDA says. The emergency authorization also allows people under age 18 to receive the vaccine if they are at high risk.

Health-care providers can now administer the shots to adults through intradermal injection, or between the layers of the skin. This will increase the supply of doses by as much as fivefold. Dr. Peter Marks, head of the FDA's vaccine division, said there has been an increase in possible exposures among children over the past week.

Jynneos is the only FDA approved monkeypox vaccine in the U.S. The shots are administered in two doses 28 days apart. Children will receive the vaccine through the typical subcutaneous injection. The intradermal injections for adults use a lower volume dosage that will allow 400,000 vials to provide up to 2 million shots.

Jynneos is manufactured by Bavarian Nordic, a biotech company based in Denmark. Demand for the shots has outstripped available supply as the monkeypox outbreak grows. The vaccine was approved by FDA in 2019 based on immune response data. There isn't data on how well the vaccine prevents disease because there were no smallpox cases.

The U.S. is fighting the largest monkeypox outbreak in the world. There are nearly 9,000 cases across 49 states, Washington D.C. and Puerto Rico. People have struggled to get appointments, which book up quickly. Monkeypox is rarely fatal and no deaths have been reported so far.
Posted by AL alphaman
Tap to Copy the Short Url to This Post: 
One-Stop Business News backed by Mark Cuban. Free to Use →